Ruiyang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruiyang Liu has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Shinkle
Department of Medicine, Washington University in St. Louis, St. Louis, Missouri
40 shared publications - Li Ding
Washington University in St. Louis
40 shared publications - Matthew A. Wyczalkowski
Department of Medicine, Washington University in St. Louis, St. Louis, USA
40 shared publications - Michael C. Wendl
Department of Medicine, Washington University in St. Louis, St. Louis, Missouri
40 shared publications - Reyka G. Jayasinghe
Washington University in St. Louis 4 Saint Louis, MO
40 shared publications - Daniel Cui Zhou
Oncology Division, Department of Medicine, Washington University in St. Louis, St. Louis, USA
39 shared publications
Latest Publications
- Open Access
Bloom unifies brain cell representations across modalities and contexts
Multimodal genomic datasets now profile mammalian brain cells across anatomical regions, developmental stages, disease states, and species. Learning shared representations that capture cellular diversity across these heterogeneous observations remains a central challenge. Here, we introduce Bloom, a transformer-based model that represents cells using gene expression, chromatin accessibility, or both. Bloom is trained on 300,000 adult mouse brain cells with paired measurements, randomly sampled with broad-subclass balancing—approximately 100-fold fewer cells than used by comparable pre-trained models. By combining genomic sequence embeddings with randomly sampled multimodal cell views, Bloom outperforms unimodal cell models in resolving brain-wide cell types and in annotation, regression, and label-transfer tasks. Its attention patterns reveal cell-type-dependent associations among genomic loci, including pairs separated by millions of base pairs. These results establish Bloom as a data-efficient framework for integrating multimodal brain cell measurements and generating hypotheses about cell-type-specific genomic relationships.
Open AccessBloom unifies brain cell representations across modalities and contexts
Multimodal genomic datasets now profile mammalian brain cells across anatomical regions, developmental stages, disease states, and species. Learning shared representations that capture cellular diversity across these heterogeneous observations remains a central challenge. Here, we introduce Bloom, a transformer-based model that represents cells using gene expression, chromatin accessibility, or both. Bloom is trained on 300,000 adult mouse brain cells with paired measurements, randomly sampled with broad-subclass balancing—approximately 100-fold fewer cells than used by comparable pre-trained models. By combining genomic sequence embeddings with randomly sampled multimodal cell views, Bloom outperforms unimodal cell models in resolving brain-wide cell types and in annotation, regression, and label-transfer tasks. Its attention patterns reveal cell-type-dependent associations among genomic loci, including pairs separated by millions of base pairs. These results establish Bloom as a data-efficient framework for integrating multimodal brain cell measurements and generating hypotheses about cell-type-specific genomic relationships.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank <0.5) are shown. Detailed explanation of each column can be found here: http://www.cbs.dtu.dk/services/NetMHC/output.php.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank <0.5) are shown. Detailed explanation of each column can be found here: http://www.cbs.dtu.dk/services/NetMHC/output.php.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Batch specific co-expression analysis.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Batch specific co-expression analysis.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
List of recurrent mutations with potential utility as neoantigens
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
List of recurrent mutations with potential utility as neoantigens
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Multiple myeloma (MM) is a highly refractory hematologic cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 MM patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single-cell transcriptomic profiling, yielding 38 MM marker genes encoding cell-surface proteins and 15 encoding intracellular proteins. Of these, 20 candidate genes were highlighted that are not yet under clinical study, 11 of which were previously uncharacterized as therapeutic targets. The findings were cross-validated using bulk RNA sequencing, flow cytometry, and proteomic mass spectrometry of MM cell lines and patient BM, demonstrating high overall concordance across data types. Independent discovery using bulk RNA sequencing reiterated top candidates, further affirming the ability of single-cell transcriptomics to accurately capture marker expression despite limitations in sample size or sequencing depth. Target dynamics and heterogeneity were further examined using both transcriptomic and immuno-imaging methods. In summary, this study presents a robust and broadly applicable strategy for identifying tumor markers to better inform the development of targeted cancer therapy.Significance:Single-cell transcriptomic profiling and multiomic cross-validation to uncover therapeutic targets identifies 38 myeloma marker genes, including 11 transcribing surface proteins with previously uncharacterized potential for targeted antitumor therapy.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Multiple myeloma (MM) is a highly refractory hematologic cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 MM patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single-cell transcriptomic profiling, yielding 38 MM marker genes encoding cell-surface proteins and 15 encoding intracellular proteins. Of these, 20 candidate genes were highlighted that are not yet under clinical study, 11 of which were previously uncharacterized as therapeutic targets. The findings were cross-validated using bulk RNA sequencing, flow cytometry, and proteomic mass spectrometry of MM cell lines and patient BM, demonstrating high overall concordance across data types. Independent discovery using bulk RNA sequencing reiterated top candidates, further affirming the ability of single-cell transcriptomics to accurately capture marker expression despite limitations in sample size or sequencing depth. Target dynamics and heterogeneity were further examined using both transcriptomic and immuno-imaging methods. In summary, this study presents a robust and broadly applicable strategy for identifying tumor markers to better inform the development of targeted cancer therapy.Significance:Single-cell transcriptomic profiling and multiomic cross-validation to uncover therapeutic targets identifies 38 myeloma marker genes, including 11 transcribing surface proteins with previously uncharacterized potential for targeted antitumor therapy.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S5 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
List of recurrent mutations with potential utility as neoantigens
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
List of recurrent mutations with potential utility as neoantigens